Roger Cady, M.D.

 

Roger Cady currently serves as Chief Medical Officer (CMO) at Nuvie Bio.

 

Roger has over 40 years of clinical experience in family medicine, pain management, and headache specialization. He authored the pivotal study on sumatriptan and has conducted research and managed patients utilizing most of the pharmacological and non-pharmacological advancements in migraine occurring over the last 30 years. He has authored over 200 peer-reviewed articles, books, and chapters of books on acute and preventive treatment of migraine. In the last eight years, he joined industry and pursued drug development for migraine. As VP of Neurology at Alder Biopharmaceuticals and later Lundbeck Pharmaceuticals, he was instrumental to the clinical development, FDA approval, and post approval advancement of eptinezumab.

 

Roger founded the Headache Care Center, an interdisciplinary clinic devoted to the care of headache patients; the Primary Care Network, a not-for-profit 501C3 dedicated to advancing the role of primary care in headache management; and Clinvest, a research network which has conducted over 600 clinical trials since its inception. Roger served as Executive VP of the National Headache Foundation.

 

Roger joined Nuvie Bio to pursue his lifetime passion of advancing clinical outcomes for people with migraine by improving their understanding and utilization of acute treatment. 

 

Roger received his M.D. degree from Mayo Medical School in Rochester, MN.